

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 June 2022 (16.06.2022)



(10) International Publication Number
WO 2022/125788 A1

(51) International Patent Classification:

A61K 9/08 (2006.01) A61K 47/10 (2017.01)
A61K 9/19 (2006.01) A61K 47/18 (2017.01)
A61K 47/02 (2006.01) A61K 38/20 (2006.01)
A61K 47/26 (2006.01) A61K 38/45 (2006.01)
A61P 35/00 (2006.01) C07K 19/00 (2006.01)

(21) International Application Number:

PCT/US2021/062631

(22) International Filing Date:

09 December 2021 (09.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/123,589 10 December 2020 (10.12.2020) US

(71) Applicant: **STEMLINE THERAPEUTICS, INC.**
[US/US]; 750 Lexington Avenue, New York, New York
10022 (US).

(72) Inventors: **CONNOLLY, Joan**; c/o Stemline Therapeutics, Inc., 750 Lexington Avenue, New York, New York 10022 (US). **ERICKSON, Frederick**; c/o Stemline Therapeutics, Inc., 750 Lexington Avenue, New York, New York 10022 (US). **KAMAT, Madhav**; c/o Stemline Therapeutics, Inc., 750 Lexington Avenue, New York, New York 10022 (US). **WASSERMAN, Jennifer**; c/o Stemline Therapeutics, Inc., 750 Lexington Avenue, New York, New York 10022 (US). **ZABRECKY, James**; c/o Stemline

Therapeutics, Inc., 750 Lexington Avenue, New York, New York 10022 (US).

(74) Agent: **MCNEILL, Rebecca M.** et al.; MCNEILL BAUR PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge, Massachusetts 02140 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: IMPROVED LYOPHILIZED FORMULATION




Fig. 1A

(57) Abstract: Provided herein are improved formulations of tagraxofusp for lyophilization used to manufacture stable formulations of tagraxofusp for intravenous injection.

[Continued on next page]

WO 2022/125788 A1

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*